Cardiff Oncology Statistics
Share Statistics
Cardiff Oncology has 66.52M shares outstanding. The number of shares has increased by 48.89% in one year.
| Shares Outstanding | 66.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 42.9% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 61.33M |
| Failed to Deliver (FTD) Shares | 850.37K |
| FTD / Avg. Volume | 42.26% |
Short Selling Information
The latest short interest is 9.95M, so 14.95% of the outstanding shares have been sold short.
| Short Interest | 9.95M |
| Short % of Shares Out | 14.95% |
| Short % of Float | 16.22% |
| Short Ratio (days to cover) | 2.92 |
Valuation Ratios
The PE ratio is -1.6 and the forward PE ratio is -3.11.
| PE Ratio | -1.6 |
| Forward PE | -3.11 |
| PS Ratio | 135.5 |
| Forward PS | 2077.6 |
| PB Ratio | 0.95 |
| P/FCF Ratio | -2.1 |
| PEG Ratio | n/a |
Enterprise Valuation
Cardiff Oncology Inc. has an Enterprise Value (EV) of 46.62M.
| EV / Earnings | -1.12 |
| EV / Sales | 95.52 |
| EV / EBITDA | -1.04 |
| EV / EBIT | -1.03 |
| EV / FCF | -1.48 |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.
| Current Ratio | 7.41 |
| Quick Ratio | 7.41 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -63.17%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -63.17% |
| Revenue Per Employee | 15.74K |
| Profits Per Employee | -1.34M |
| Employee Count | 31 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 198.09% in the last 52 weeks. The beta is 1.93, so Cardiff Oncology 's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | 198.09% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 3.18 |
| Relative Strength Index (RSI) | 63.28 |
| Average Volume (20 Days) | 2.01M |
Income Statement
In the last 12 months, Cardiff Oncology had revenue of 488.00K and earned -41.44M in profits. Earnings per share was -0.93.
| Revenue | 488.00K |
| Gross Profit | 488.00K |
| Operating Income | -45.41M |
| Net Income | -41.44M |
| EBITDA | -45.01M |
| EBIT | -45.41M |
| Earnings Per Share (EPS) | -0.93 |
Balance Sheet
The company has 21.66M in cash and 2.15M in debt, giving a net cash position of 19.51M.
| Cash & Cash Equivalents | 21.66M |
| Total Debt | 2.15M |
| Net Cash | 19.51M |
| Retained Earnings | -339.54M |
| Total Assets | 62.90M |
| Working Capital | 46.81M |
Cash Flow
In the last 12 months, operating cash flow was -30.89M and capital expenditures -582.00K, giving a free cash flow of -31.47M.
| Operating Cash Flow | -30.89M |
| Capital Expenditures | -582.00K |
| Free Cash Flow | -31.47M |
| FCF Per Share | -0.7 |
Margins
Gross margin is 10.00K%, with operating and profit margins of -930.57K% and -849.20K%.
| Gross Margin | 10.00K% |
| Operating Margin | -930.57K% |
| Pretax Margin | -849.20K% |
| Profit Margin | -849.20K% |
| EBITDA Margin | -9.22K% |
| EBIT Margin | -9.31K% |
| FCF Margin | -6.45K% |
Dividends & Yields
CRDF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -19.87% |
| FCF Yield | -10.1% |
Analyst Forecast
The average price target for CRDF is $10, which is 113.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 113.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Feb 20, 2019. It was a backward split with a ratio of 1:6.
| Last Split Date | Feb 20, 2019 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 1.77 |
| Piotroski F-Score | 3 |